Molecular evidence for BDNF-and GABA-related dysfunctions in the amygdala of female subjects with major depression

Molecular Psychiatry

Volumn 17, Issue 11, 2012, Pages 1130-1142

  Guilloux, J P ^a,b   Douillard Guilloux, G ^a   Kota, R ^a   Wang, X ^c   Gardier, A M ^b   Martinowich, K ^d   Tseng, G C ^c   Lewis, D A ^a,e   Sibille, E ^a,e  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b University of Paris XI   (France)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

amygdala; BDNF; female; GABA; major depression; neurotrophic hypothesis; somatostatin

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CORTISTATIN; FLUOXETINE; NEUROPEPTIDE Y; SOMATOSTATIN; TACHYKININ;

ADOLESCENT; ADULT; AMYGDALOID NUCLEUS; ARTICLE; AUTOPSY; BRAIN DYSFUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GENE EXPRESSION; GENETIC CODE; HUMAN; HYPOTHESIS; MAJOR DEPRESSION; MOLECULAR BIOLOGY; MOOD; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RECEPTOR DOWN REGULATION; TRANSCRIPTION REGULATION;

ADOLESCENT; ADULT; AGED; AMYGDALA; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; DOWN-REGULATION; FEMALE; GABAERGIC NEURONS; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION STUDIES; HUMANS; MICE; MICE, KNOCKOUT; MIDDLE AGED; NEUROPEPTIDE Y; NEUROPEPTIDES; SOMATOSTATIN; TACHYKININS;

EID: 84867898404     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2011.113     Document Type: Article

References (78)

1. Cotter D, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 2001; 58: 545-553. (Pubitemid 32523734)
2. Rajkowska G, Halaris A, Selemon LD. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 2001; 49: 741-752. (Pubitemid 32452295)
3. Bowley MP, Drevets WC, Ongur D, Price JL. Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry 2002; 52: 404-412. (Pubitemid 35266731)
4. Hamidi M, Drevets WC, Price JL. Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiatry 2004; 55: 563-569. (Pubitemid 38315029)
5. Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry 2004; 161: 1957-1966. (Pubitemid 39441394)
6. Campbell S, Marriott M, Nahmias C, MacQueen GM. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry 2004; 161: 598-607. (Pubitemid 38445502)
7. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002; 22: 3251-3261. (Pubitemid 35379212)
8. Deltheil T, Tanaka K, Reperant C, Hen R, David DJ, Gardier AM. Synergistic neurochemical and behavioural effects of acute intrahippocampal injection of brain-derived neurotrophic factor and antidepressants in adult mice. Int J Neuropsychopharmacol 2009; 12: 905-915.
9. Monteggia LM, Barrot M, Powell CM, Berton O, Galanis V, Gemelli T et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci USA 2004; 101: 10827-10832. (Pubitemid 38955827)
10. Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDonald E et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 2003; 23: 349-357. (Pubitemid 36050437)
11. Molendijk ML, Bus BA, Spinhoven P, Penninx BW, Kenis G, Prickaerts J et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2010 (in press).
12. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008; 64: 527-532.
13. Dunham JS, Deakin JF, Miyajima F, Payton A, Toro CT. Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. J Psychiatr Res 2009; 43: 1175-1184.
14. Thompson Ray M, Weickert CS, Wyatt E, Webster MJ. Decreased BDNF, trkB-TK + and GAD(67) mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J Psychiatry Neurosci 2011; 36: 100048.
15. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001; 50: 260-265. (Pubitemid 32778442)
16. Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003; 60: 804-815. (Pubitemid 36960912)
17. Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res 2005; 136: 29-37. (Pubitemid 40704606)
18. Kozicz T, Tilburg-Ouwens D, Faludi G, Palkovits M, Roubos E. Gender-related urocortin 1 and brain-derived neurotrophic factor expression in the adult human midbrain of suicide victims with major depression. Neuroscience 2008; 152: 1015-1023.
19. Ernst C, Deleva V, Deng X, Sequeira A, Pomarenski A, Klempan T et al. Alternative splicing, methylation state, and expression profile of tropomyosin-related kinase B in the frontal cortex of suicide completers. Arch Gen Psychiatry 2009; 66: 22-32.
20. Keller S, Sarchiapone M, Zarrilli F, Videtic A, Ferraro A, Carli V et al. Increased BDNF promoter methylation in the Wernicke area of suicide subjects. Arch Gen Psychiatry 2010; 67: 258-267.
21. Pregelj P, Nedic G, Paska AV, Zupanc T, Nikolac M, Balazic J et al. The association between brain-derived neurotrophic factor polymorphism (BDNF Val66Met) and suicide. J Affect Disord 2011; 128: 287-290.
22. Sequeira A, Mamdani F, Ernst C, Vawter MP, Bunney WE, Lebel V et al. Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS One 2009; 4: e6585.
23. Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004; 61: 705-713. (Pubitemid 38890805)
24. Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder F, Petroff OA et al. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 1999; 56: 1043-1047. (Pubitemid 29526389)
25. Levinson AJ, Fitzgerald PB, Favalli G, Blumberger DM, Daigle M, Daskalakis ZJ. Evidence of cortical inhibitory deficits in major depressive disorder. Biol Psychiatry 2010; 67: 458-464.
26. Sibille E, Morris HM, Kota RS, Lewis DA. GABA-related transcripts in the dorsolateral prefrontal cortex in mood disorders. Int J Neuropsychopharmacol 2011; 14: 721-734.
27. Tripp A, Kota RS, Lewis DA, Sibille E. Reduced somatostatin in subgenual anterior cingulate cortex in major depression. Neurobiol Dis 2011; 42: 116-124.
28. Glorioso C, Sabatini M, Unger T, Hashimoto T, Monteggia LM, Lewis DA et al. Specificity and timing of neocortical transcriptome changes in response to BDNF gene ablation during embryogenesis or adulthood. Mol Psychiatry 2006; 11: 633-648. (Pubitemid 43989811)
29. Muller JF, Mascagni F, McDonald AJ. Postsynaptic targets of somatostatin-containing interneurons in the rat basolateral amygdala. J Comp Neurol 2007; 500: 513-529.
30. Seminowicz DA, Mayberg HS, McIntosh AR, Goldapple K, Kennedy S, Segal Z et al. Limbic-frontal circuitry in major depression: a path modeling metanalysis. Neuroimage 2004; 22: 409-418. (Pubitemid 38515850)
31. Pezawas L, Meyer-Lindenberg A, Goldman AL, Verchinski BA, Chen G, Kolachana BS et al. Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression. Mol Psychiatry 2008; 13: 709-716. (Pubitemid 351861533)
32. Hamilton JP, Gotlib IH. Neural substrates of increased memory sensitivity for negative stimuli in major depression. Biol Psychiatry 2008; 63: 1155-1162.
33. Glantz LA, Lewis DA. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. Arch Gen Psychiatry 1997; 54: 943-952. (Pubitemid 128719705)
34. Sibille E, Wang Y, Joeyen-Waldorf J, Gaiteri C, Surget A, Oh S et al. A molecular signature of depression in the amygdala. Am J Psychiatry 2009; 166: 1011-1024.
35. Benjamini Y, Hochberg Y. Controlling the false discovery rate-a practical and powerful approach to multiple testing. J Roy Stat Soc B Met 1995; 57: 289-300.
36. Morris HM, Hashimoto T, Lewis DA. Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder. Cereb Cortex 2008; 18: 1575-1587. (Pubitemid 351882034)
37. Korte M, Carroll P, Wolf E, Brem G, Thoenen H, Bonhoeffer T. Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc Natl Acad Sci USA 1995; 92: 8856-8860.
38. Sakata K, Woo NH, Martinowich K, Greene JS, Schloesser RJ, Shen L et al. Critical role of promoter IV-driven BDNF transcription in GABAergic transmission and synaptic plasticity in the prefrontal cortex. Proc Natl Acad Sci USA 2009; 106: 5942-5947.
39. Franklin KBJ, Paxinos G. The Mouse Brain in Stereotaxic Coordinates, 3rd edn. Academic Press: New York, 2008, xxv, 1 v. pp (various pagings).
40. Sibille E, Arango V, Joeyen-Waldorf J, Wang Y, Leman S, Surget A et al. Large-scale estimates of cellular origins of mRNAs: enhancing the yield of transcriptome analyses. J Neurosci Methods 2008; 167: 198-206. (Pubitemid 350235629)
41. Bloom FE, Morales M. The central 5-HT3 receptor in CNS disorders. Neurochem Res 1998; 23: 653-659. (Pubitemid 28173570)
42. Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T. Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 2007; 90: 397-406. (Pubitemid 47179877)
43. Erraji-BenChekroun L, Underwood MD, Arango V, Galfalvy HC, Pavlidis P, Smyrniotopoulos P et al. Molecular aging in human prefrontal cortex is selective and continuous throughout adult life. Biological Psychiatry 2005; 57: 549-558. (Pubitemid 40311991)
44. Guilloux JP, Seney M, Edgar N, Sibille E. Integrated behavioral z-scoring increases the sensitivity and reliability of behavioral phenotyping in mice: relevance to emotionality and sex. J Neurosci Methods 2011; 197: 21-31.
45. van Disseldorp J, Faddy MJ, Themmen AP, de Jong FH, Peeters PH, van der Schouw YT et al. Relationship of serum antimullerian hormone concentration to age at menopause. J Clin Endocrinol Metab 2008; 93: 2129-2134. (Pubitemid 351831526)
46. Takei N, Sasaoka K, Inoue K, Takahashi M, Endo Y, Hatanaka H. Brain-derived neurotrophic factor increases the stimulationevoked release of glutamate and the levels of exocytosis-associated proteins in cultured cortical neurons from embryonic rats. J Neurochem 1997; 68: 370-375. (Pubitemid 26427330)
47. Fatemi SH, Earle JA, Stary JM, Lee S, Sedgewick J. Altered levels of the synaptosomal associated protein SNAP-25 in hippocampus of subjects with mood disorders and schizophrenia. Neuroreport 2001; 12: 3257-3262. (Pubitemid 33010654)
48. Lewis DA, Campbell MJ, Morrison JH. An immunohistochemical characterization of somatostatin-28 and somatostatin-281-12 in monkey prefrontal cortex. J Comp Neurol 1986; 248: 1-18. (Pubitemid 16076497)
49. Glorioso C, Oh S, Douillard GG, Sibille E. Brain molecular aging, promotion of neurological disease and modulation by Sirtuin5 longevity gene polymorphism. Neurobiol Dis 2011; 41: 279-290.
50. Russo-Neustadt A, Beard RC, Cotman CW. Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology 1999; 21: 679-682. (Pubitemid 29486636)
51. Duman RS, Monteggia LM. A neurotrophic model for stressrelated mood disorders. Biol Psychiatry 2006; 59: 1116-1127.
52. Mattson MP, Maudsley S, Martin B. A neural signaling triumvirate that influences ageing and age-related disease: insulin/IGF-1, BDNF and serotonin. Ageing Res Rev 2004; 3: 445-464. (Pubitemid 39487900)
53. Buckley PF, Mahadik S, Pillai A, Terry Jr A. Neurotrophins and schizophrenia. Schizophr Res 2007; 94: 1-11. (Pubitemid 47033973)
54. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 2009; 5: 311-322.
55. Gahete MD, Rubio A, Duran-Prado M, Avila J, Luque RM, Castano JP. Expression of Somatostatin, cortistatin, and their receptors, as well as dopamine receptors, but not of neprilysin, are reduced in the temporal lobe of Alzheimer's disease patients. J Alzheimers Dis 2010; 20: 465-475.
56. Fino E, Yuste R. Dense inhibitory connectivity in neocortex. Neuron 2011; 69: 1188-1203.
57. Hashimoto T, Volk DW, Eggan SM, Mirnics K, Pierri JN, Sun Z et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 2003; 23: 6315-6326. (Pubitemid 36875633)
58. Siegle GJ, Thompson W, Carter CS, Steinhauer SR, Thase ME. Increased amygdala and decreased dorsolateral prefrontal BOLD responses in unipolar depression: related and independent features. Biol Psychiatry 2007; 61: 198-209. (Pubitemid 46072788)
59. Tsankova NM, Berton O, RenthalW, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006; 9: 519-525.
60. Surget A, Wang Y, Leman S, Ibarguen-Vargas Y, Edgar N, Griebel G et al. Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal. Neuropsychopharmacology 2009; 34: 1363-1380.
61. Chourbaji S, Hellweg R, Brandis D, Zorner B, Zacher C, Lang UE et al. Mice with reduced brain-derived neurotrophic factor expression show decreased choline acetyltransferase activity, but regular brain monoamine levels and unaltered emotional behavior. Brain Res Mol Brain Res 2004; 121: 28-36. (Pubitemid 38224167)
62. Ibarguen-Vargas Y, Surget A, Vourc'h P, Leman S, Andres CR, Gardier AM et al. Deficit in BDNF does not increase vulnerability to stress but dampens antidepressant-like effects in the unpredictable chronic mild stress. Behav Brain Res 2009; 202: 245-251.
63. Berton O, McClung CA, DiLeone RJ, Krishnan V, Renthal W, Russo SJ et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006; 311: 864-868. (Pubitemid 43228853)
64. Autry AE, Adachi M, Cheng P, Monteggia LM. Gender-specific impact of brain-derived neurotrophic factor signaling on stressinduced depression-like behavior. Biol Psychiatry 2009; 66: 84-90.
65. Monteggia LM, Luikart B, Barrot M, Theobold D, Malkovska I, Nef S et al. Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biol Psychiatry 2007; 61: 187-197. (Pubitemid 46072778)
66. Advani T, KoekW, Hensler JG. Gender differences in the enhanced vulnerability of BDNF +mice to mild stress. Int J Neuropsychopharmacol 2009; 12: 583-588.
67. Sakata K, Jin L, Jha S. Lack of promoter IV-driven BDNF transcription results in depression-like behavior. Genes Brain Behav 2010; 9: 712-721.
68. Zeyda T, Diehl N, Paylor R, Brennan MB, Hochgeschwender U. Impairment in motor learning of somatostatin null mutant mice. Brain Res 2001; 906: 107-114. (Pubitemid 32595544)
69. Engin E, Stellbrink J, Treit D, Dickson CT. Anxiolytic and antidepressant effects of intracerebroventricularly administered somatostatin: behavioral and neurophysiological evidence. Neuroscience 2008; 157: 666-676.
70. Gatt JM, Nemeroff CB, Dobson-Stone C, Paul RH, Bryant RA, Schofield PR et al. Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol Psychiatry 2009; 14: 681-695.
71. Lau JY, Goldman D, Buzas B, Hodgkinson C, Leibenluft E, Nelson E et al. BDNF gene polymorphism (Val66Met) predicts amygdala and anterior hippocampus responses to emotional faces in anxious and depressed adolescents. Neuroimage 2010; 53: 952-961.
72. Mickey BJ, Zhou Z, Heitzeg MM, Heinz E, Hodgkinson CA, Hsu DT et al. Emotion processing, major depression, and functional genetic variation of neuropeptide Y. Arch Gen Psychiatry 2011; 68: 158-166.
73. Zhou Z, Zhu G, Hariri AR, Enoch MA, Scott D, Sinha R et al. Genetic variation in human NPYexpression affects stress response and emotion. Nature 2008; 452: 997-1001. (Pubitemid 351589618)
74. Ogden CA, Rich ME, Schork NJ, Paulus MP, Geyer MA, Lohr JB et al. Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach. Mol Psychiatry 2004; 9: 1007-1029. (Pubitemid 39524290)
75. Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry 2001; 6: 293-301. (Pubitemid 32275674)
76. Rethelyi JM, Bakker SC, Polgar P, Czobor P, Strengman E, Pasztor PI et al. Association study of NRG1, DTNBP1, RGS4, G72/G30, and PIP5K2Awith schizophrenia and symptom severity in a Hungarian sample. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 792-801.
77. Etain B, Dumaine A, Mathieu F, Chevalier F, Henry C, Kahn JP et al. A SNAP25 promoter variant is associated with early-onset bipolar disorder and a high expression level in brain. Mol Psychiatry 2010; 15: 748-755.
78. Mai JK, Assheuer J, Paxinos G. Atlas of the Human Brain, 2nd edn. Elsevier Academic Press: Amsterdam, Boston, 2004, viii, 246 p.